Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.

Anticancer research - 1 May 2015

Hong Jung Yong, Seo Ja-Young, Kim Sun-Hee, Jung Hyun Ae, Park Silvia, Kim Kihyun, Jung Chul Won, Kim Jin Seok, Park Joon Seong, Kim Hee-Jin, Jang Jun Ho

Abstract excerpt

BACKGROUND: Hypomethylating agents, such as azacitidine and decitabine, now constitute one of the mainstays of myelodysplastic syndrome (MDS) treatment. In recent years, novel recurrent mutations in multiple genes encoding RNA spliceosomal machinery (SRSF2, U2AF1, ZRSR2, SF3B1) were revealed. However, the clinical impact of these mutations on the outcomes of treatment of MDS patients with hypomethylating agents...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Decitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Ribonucleoproteins

Share to RNA Splicing

Share to Serine-Arginine Splicing Factors

Share to Spliceosomes

Share to Splicing Factor U2AF

Source

Identifiers

PMID: 25964599

Genes

SRSF2
ZRSR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.PMID 25964599Read ↗

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.Semantic proximity Read ↗

RNA splicing as a therapeutic target in myelodysplastic syndromes.Semantic proximity Read ↗

Frequent Pathway Mutations of Splicing Machinery in MyelodysplasiaSemantic proximity Read ↗

Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemiaSemantic proximity Read ↗

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.Semantic proximity Read ↗

Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.Semantic proximity Read ↗

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.Semantic proximity Read ↗

Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.Semantic proximity Read ↗

Clinical and prognostic profile of SRSF2 and related spliceosome mutations in patients with acute myeloid leukemia.Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.Semantic proximity Read ↗

[Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.